p16INK4A (CDKN2A) Mouse Monoclonal Antibody [Clone ID: OTI4C11]

CAT#: CF500036

Carrier-free (BSA/glycerol-free) P16 mouse monoclonal antibody, clone OTI4C11 (formerly 4C11)

Product Images

HEK293T cells were transfected with the pCMV6-ENTRY control (Cat# PS100001, Left lane) or pCMV6-ENTRY P16 (Cat# RC220937, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-P16(Cat# TA500036). Positive lysates LY400022 (100ug) and LC400022 (20ug) can be purchased separately from OriGene.

• 

  Western blot analysis of extracts (35ug) from 9 different cell lines by using anti-P16 monoclonal antibody.

• 

  Immunohistochemical staining of paraffin-embedded Human liver tissue within the normal limits using anti-P16 mouse monoclonal antibody. (TA500036)

• 

  Immunohistochemical staining of paraffin-embedded Carcinoma of Human liver tissue using anti-P16 mouse monoclonal antibody. (TA500036)

• 

  Immunohistochemical staining of paraffin-embedded Carcinoma of Human thyroid tissue using anti-P16 mouse monoclonal antibody. (TA500036)

• 

  Immunohistochemical staining of paraffin-embedded Adenocarcinoma of Human endometrium tissue using anti-P16 mouse monoclonal antibody. (TA500036)

• Anti-P16 mouse monoclonal antibody (TA500036) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY P16 (RC220937).

• Immunofluorescent staining of HeLa cells using anti-P16 mouse monoclonal antibody (TA500036).

• Immunofluorescent staining of HepG2 cells using anti-P16 mouse monoclonal antibody (TA500036).

Show all 9 images

Specifications

Product Data

• Clone Name: OTI4C11
• Applications: IF, IHC, WB
• Recommended Dilution: WB 1:1000, IF 1:100, IHC 1:150
• Reactivities: Human
• Host: Mouse
• Isotype: IgG1
• Clonality: Monoclonal
• Immunogen: Full length human recombinant protein of human CDKN2A (NP_000068) produced in E.coli.
• Formulation: Lyophilized powder (original buffer 1X PBS, pH 7.3, 8% trehalose)
• Reconstitution Method: For reconstitution, we recommend adding 100uL distilled water to a final antibody concentration of about 1 mg/mL. To use this carrier-free antibody for conjugation experiment, we strongly recommend performing another round of desalting process. (OriGene recommends Zeba Spin Desalting Columns, 7KMWCO from Thermo Scientific)
• Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
• Conjugation: Unconjugated
• Storage: Store at -20°C as received.
• Stability: Stable for 12 months from date of receipt.
• Predicted Protein Size: 16.4 kDa
• Gene Name: cyclin dependent kinase inhibitor 2A
• Database Link:
  NP_000068
  Entrez Gene 1029 Human
  UniProt ID Q8N726
• Background: P16 gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, MDM1, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.
• Synonyms: ARF; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4

Reference Data

• Protein Families: Druggable Genome
• Protein Pathways: Bladder cancer, Cell cycle, Chronic myeloid leukemia, Glioma, Melanoma, Non-small cell lung cancer, p53 signaling pathway, Pancreatic cancer, Pathways in cancer